Featured Research

from universities, journals, and other organizations

Improving efficacy of antipsychotics in the era of personalized pharmacotherapy

Date:
December 9, 2013
Source:
Université de Montréal
Summary:
The efficacy of most antipsychotics depends on their pharmacokinetics, or their ability to get into the bloodstream after being absorbed. According to data recently collected, five of the most recent second-generation antipsychotics were among the drugs with the lowest efficacy, despite having similar pharmacological properties compared to first-generation or to other second-generation antipsychotics.

The clinical context of the administration and dosage of antipsychotics may influence their efficacy, reported Philippe Vincent and Édouard Kouassi, from the Institut universitaire en santé mentale de Montréal and Université de Montréal. The efficacy of most antipsychotics depends on their pharmacokinetics, or their ability to get into the bloodstream after being absorbed.

Vincent and Kouassi are responding in The Lancet to Stefan Leucht, who conducted a meta-analysis of over 200 articles on the efficacy and side effects of 15 antipsychotics. According to the data Leucht collected, five of the most recent second-generation antipsychotics (ziprasidone, aripiprazole, asenapine, iloperidone and lurasidone) were among the drugs with the lowest efficacy, despite having similar pharmacological properties compared to first-generation or to other second-generation antipsychotics. Leucht published his finding in The Lancet in September 2013; his article did not give any explanations for this surprising result.

Some antipsychotics require strict adherence on the part of patients. According to Vincent and Kouassi, specific conditions are required for some medications to be effectively absorbed. "For example, ziprasidone needs to be taken twice a day with a meal of 500 calories, whereas asenapine must absolutely melt under the tongue, and the patient must abstain from swallowing it, drinking, eating or smoking for 10 minutes afterward," Vincent said "This is a major challenge since more than one half of people with psychotic disorders do not take their medication as prescribed.

Vincent and Kouassi also state that the titration of these antipsychotics is a challenge in clinical practice, as it is difficult to obtain the optimal therapeutic dosage on the first try. Doctors therefore have to use an empirical approach. "The major side effects show up well before the optimum therapeutic dose is determined, which can discourage patients from continuing their treatment," Kouassi said. "Doctors have to keep trying, as the pharmacokinetics of antipsychotic compounds differ for each patient. By adjusting the dose of a medication based on the degree of blood absorption, distribution, metabolism and elimination in a patient, doctors can personalize treatment, which becomes that much more effective. We maintain that all antipsychotics, with the exception of clozapine, can achieve the same efficacy if they reach comparable blood levels."

If the studies reported by Leucht had compared medications in terms of their blood concentrations, we would have more accurate conclusions about the efficacy of the medication. "This confirms that the future of psychiatric medicine will involve personalizing patient care," Vincent said.


Story Source:

The above story is based on materials provided by Université de Montréal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vincent P, Kouassi E. Efficacy of antipsychotic drugs for schizophrenia. The Lancet, December 2013.

Cite This Page:

Université de Montréal. "Improving efficacy of antipsychotics in the era of personalized pharmacotherapy." ScienceDaily. ScienceDaily, 9 December 2013. <www.sciencedaily.com/releases/2013/12/131209085553.htm>.
Université de Montréal. (2013, December 9). Improving efficacy of antipsychotics in the era of personalized pharmacotherapy. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2013/12/131209085553.htm
Université de Montréal. "Improving efficacy of antipsychotics in the era of personalized pharmacotherapy." ScienceDaily. www.sciencedaily.com/releases/2013/12/131209085553.htm (accessed July 28, 2014).

Share This




More Mind & Brain News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Losing Sleep Leaves You Vulnerable To 'False Memories'

Losing Sleep Leaves You Vulnerable To 'False Memories'

Newsy (July 27, 2014) — A new study shows sleep deprivation can make it harder for people to remember specific details of an event. Video provided by Newsy
Powered by NewsLook.com
University Quiz Implies Atheists Are Smarter Than Christians

University Quiz Implies Atheists Are Smarter Than Christians

Newsy (July 25, 2014) — An online quiz from a required course at Ohio State is making waves for suggesting atheists are inherently smarter than Christians. Video provided by Newsy
Powered by NewsLook.com
Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) — A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins